PTO/SB/08a (05-07)
Approved for use through 09/30/2007 OMB 0851-0031
U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE to a collection of information unless it contains a valid OMB control number. 10508510

	Application Number		10390310	
NFORMATION DISCLOSURE STATEMENT BY APPLICANT Not for submission under 37 CFR 1.99)	Filing Date		2006-09-01	
	First Named Inventor Akira		a Higuchi	
	Art Unit			
	Examiner Name			
	Attorney Docket Numb	er	41182	

					U.S.	PATENTS			Remove		
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue [sue Date Name of Patentee or Applicant				Pages,Columns,Lines where Relevant Passages or Relevan Figures Appear		
	1										
If you wis	h to a	l dd additional U.S. Patei	nt citatio	n inform	ation pl	ease click the	Add button.		Add		_
			U.S.P	ATENT	APPLI	CATION PUBL	LICATIONS		Remove		
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publica Date	tion	Name of Pate of cited Docu	entee or Applicant ment	Releva	Columns,Line nt Passages o Appear		
	1										
If you wis	h to a	dd additional U.S. Publi		,		information p		d button	Add		
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²	,	Kind Code ⁴	Publication	Name of Patente Applicant of cited Document	e or v	Pages,Column where Relevan Passages or R rigures Appea	t elevant	T=
	1	2002-509255	JP			2002-03-26					
	2	01-38883	wo			2001-05-31	Nihon Parkerizing Hiroshma Co., Ltd				
	3	03-174169	JP			1991-07-29	Ricoh Co., Ltd.				

Application Number 10596510 Fing Date 2006 49 01 Fing Date 10596510 Fi

	4	2004	-085521	JP		2004-03-18	Nippon Support System KK		
If you wish to add additional Foreign Patent Document citation information please click the Add button Add									
NON-PATENT LITERATURE DOCUMENTS Remove									
Examiner Initials*	Examiner Cite Include name of the author (in CAPITAL LETTERS), itsel of the article (when appropriate), itsel of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city andor country where published.								Τö
1 Japanese Office Action Dated July 10, 2007									
If you wish to add additional non-patent literature document citation information please click the Add button Add									
EXAMINER SIGNATURE									
Examiner	r Signa	ature					Date Considered		

See Kind Codes of USPTO Petent Documents at invest, ISPTO, DDL/or KMPEP 601.04. 2 Enter office that issued the document, by the involved code (WIPO) Standard S13.3 - For Lapraence parter fourments, the articulation of the parent of the register or the present or serial review of the opation of the parent of the parent or many review of the parent or many review of the parent or many review or the parent document. If while of the parent or the par

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99) APPLICANT (Not for submission under 37 CFR 1.99)

Attorney Docket Number 4

41182

Diagon con	27	CED .	1 07	and t	00 4	a maka	the	appropriate	coloction/c	۸.

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patient office in a counterpart foreign application not more than three months prior to the filling of the information disclosure statement. See 37 CFR 137(e)(1).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquity, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 156(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 157(4)(c)

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

Jeffrey J. Sopko

▼ None

Name/Print

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Registration Number

27676

-			
Signature /je	effrey j sopko/	Date (YYYY-MM-DD)	2007-09-20

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file fand by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C. 12.0 and 3T CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete his form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Tradenary Cfiler. U.S. Operatment of Commence, P. 0. Box 1450, Alexandria, V.S. 2313-1450. D. ONT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.S. 2313-1450.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the stacked form related to a petient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) familishing of the information solicided is civulating; and (3) the principal purpuse for which the information is used by the U.S. Patient and Trademan Coffice is to process and/or cosmisting your submission related to a patient agricultant or patient. If you do not furnish the requested process and/or cosmisting your submission related to a patient agricultant or patient. If you do not furnish the requested process and the principal principal patients and the principal principal patients and the principal principal patients and the principal patients and the principal patients and the principal patients are patients. The principal patients are provided to the principal patients and the principal patients are patients. The principal patients are principally and the principal patients are principally as a patient of the patients and the principal patients are principally as a patient of the patients and the patients are provided to the patients and the patients are principally as a patient patients are principally as a patient patients and the patients are principally as a principal patient patients. The patients are patients are patients and the patients are patients and the patients are patients and the patients are patients. The patients are patients are patients are patients and the patients are patients and the patients are patients are patients. The patients are patients are patients are patients and the patients are patients are patients are patients. The patients are patients. The patients are patients are patients ar

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these cords.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record perfains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552(m).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
 - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uturing an insection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 4d U.S.C. 2904 and 2905. Such disclosure shall be made in accordance with the GSA requisions governing inseption of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the
 application pursuant to 35 U.S.C. 12(2) to rissuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be
 disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filled in application
 which became abandoned or in which the proceedings were terminated and which application is referenced by either a
 published application, an application open to public inspections or as issued patent.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.